Shared on 05 Sep 25
Analysts maintained their $28.29 price target for Mersana Therapeutics following a reverse stock split and updated Q2 2025 financials, with continued optimism regarding Emi-Le’s clinical progress and long-term prospects. Analyst Commentary Price target reductions primarily reflect adjustments for the 1-for-25 reverse stock split rather than changes in fundamental outlook.
Shared on 01 Aug 25
Fair value Increased 560%The notable upward revision in Mersana Therapeutics' price target appears driven by improved net profit margin despite slightly weaker revenue growth forecasts, resulting in a new consensus analyst price target of $123.29. What's in the News Mersana Therapeutics will implement a 1-for-25 reverse stock split to comply with Nasdaq minimum bid price requirements.
Shared on 24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 8.07%AnalystConsensusTarget has decreased revenue growth from 8.6% to -19.6%, increased profit margin from 10.5% to 17.3%, increased future PE multiple from 148.8x to 210.4x and increased shares outstanding growth rate from 0.0% to 0.0%.